The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011.
“Today’s decision is yet another affirmation of the strength of the intellectual property behind Lipitor,” said Pfizer general counsel Allen Waxman.